Project title
以尿液外泌體甲狀腺球蛋白及半乳糖凝集素-3新型生物指標追蹤甲狀腺癌預後及再發之前瞻性研究
Internal ID
MOST107-2314-B002-024-MY3
Principal Investigator
Start Date
August 1, 2019
End Date
July 31, 2020
Investigators
Organizations
Partner Organizations
A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 = 以尿液外泌體甲狀腺球蛋白及半乳糖凝集素-3新型生物指標追蹤甲狀腺癌預後及再發之前瞻性研究
Keywords
外泌體
甲狀腺乳突癌
甲狀腺濾泡癌
甲狀腺未分化癌
蛋白質學
尿液
生物指標
甲狀腺球蛋白
半乳凝素-3
Exosome
Thyroid papillary cancer
Thyroid follicular cancer
Anaplastic thyroid cancer
Proteomics
Urine
Biological marker
Thyroglobulin
Galectin-3
Description
Although thyroid cancers are low-grade endocrine malignancy, most patients usually received thyroidectomy with ablative radioactive iodine therapy. Such patients were followed with thyroid ultrasonography and serial serum thyroglobulin evaluation. Prior researches indicated that one-third well-differentiated thyroid cancers could transform to poorly-differentiated patterns, even to be anaplastic thyroid cancer (ATC), a fatal malignancy, and no effective therapeutic strategies was noted, including surgical intervention, chemotherapy and radiotherapy. The poorly-differentiated or anaplstic change of thyroid cancer cells proliferates rapidly and always invades local tissues with distant metastasis. Cellular de-differentiation is the most pivotal cause for malignant transformation and invasion. De-differentiation usually in papillary thyroid cancer and follicular thyroid cancer, and definitely in ATC. Therefore, we try to find the biological markers and therapeutic targets via the exosomal expression in urine. On the continuing basis of prior ATC cells culture experiments. Exosomes are nanovesicles secreted into extracellular environments. Cancer cell-derived exosomes could be found in plasma, saliva, urine and other body fluid of patients with cancer. We try to analyze the urinary exosomal proteins, including thyroglobulin and galectin-3, to find the early prognostic biological markers in urine via this prospective study We expected to enroll 150 post-operative patients with papillary, follicular or anaplastic thyroid cancer, and collect their urine samples in outpatient clinic per year for at least three consecutive years. We will analyze the urine exosomal proteins and probable biological markers, including thyroglobulin and galectin-3. We hope to find the prognostic biological markers via this prospective study. We further hope to find newly therapeutic and follow-up pathway for such patients with well-differentiated or anaplastic thyroid cancer.